Company intelligence / Profile preview

T&C Neuromax

Suwon, South Korea

Ownership: Private
Development stage: Other

Overview

T&C Neuromax is a clinical-stage biotechnology company based in South Korea that specializes in the development of innovative therapies for central nervous system (CNS) disorders. The company's primary focus is on modulating the NMDA receptor pathway to treat conditions such as schizophrenia and cognitive impairment associated with Alzheimer's disease. Their lead candidate, TCN-001, is a D-amino acid oxidase (DAAO) inhibitor designed to increase D-serine levels in the brain, thereby enhancing NMDA receptor function. T&C Neuromax aims to address significant unmet medical needs in psychiatry and neurology through its targeted small molecule pipeline.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on T&C Neuromax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T&C Neuromax.

Explore the full profile